🇺🇸 FDA
Pipeline program

Infanrix hexa

201330

Approved mab completed

Quick answer

Infanrix hexa for Acellular Pertussis is a Approved program (mab) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline
Indication
Acellular Pertussis
Phase
Approved
Modality
mab
Status
completed

Clinical trials